Cargando…

Nanoparticle Vaccines Against Infectious Diseases

Due to emergence of new variants of pathogenic micro-organisms the treatment and immunization of infectious diseases have become a great challenge in the past few years. In the context of vaccine development remarkable efforts have been made to develop new vaccines and also to improve the efficacy o...

Descripción completa

Detalles Bibliográficos
Autores principales: Pati, Rashmirekha, Shevtsov, Maxim, Sonawane, Avinash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180194/
https://www.ncbi.nlm.nih.gov/pubmed/30337923
http://dx.doi.org/10.3389/fimmu.2018.02224
_version_ 1783362150738165760
author Pati, Rashmirekha
Shevtsov, Maxim
Sonawane, Avinash
author_facet Pati, Rashmirekha
Shevtsov, Maxim
Sonawane, Avinash
author_sort Pati, Rashmirekha
collection PubMed
description Due to emergence of new variants of pathogenic micro-organisms the treatment and immunization of infectious diseases have become a great challenge in the past few years. In the context of vaccine development remarkable efforts have been made to develop new vaccines and also to improve the efficacy of existing vaccines against specific diseases. To date, some vaccines are developed from protein subunits or killed pathogens, whilst several vaccines are based on live-attenuated organisms, which carry the risk of regaining their pathogenicity under certain immunocompromised conditions. To avoid this, the development of risk-free effective vaccines in conjunction with adequate delivery systems are considered as an imperative need to obtain desired humoral and cell-mediated immunity against infectious diseases. In the last several years, the use of nanoparticle-based vaccines has received a great attention to improve vaccine efficacy, immunization strategies, and targeted delivery to achieve desired immune responses at the cellular level. To improve vaccine efficacy, these nanocarriers should protect the antigens from premature proteolytic degradation, facilitate antigen uptake and processing by antigen presenting cells, control release, and should be safe for human use. Nanocarriers composed of lipids, proteins, metals or polymers have already been used to attain some of these attributes. In this context, several physico-chemical properties of nanoparticles play an important role in the determination of vaccine efficacy. This review article focuses on the applications of nanocarrier-based vaccine formulations and the strategies used for the functionalization of nanoparticles to accomplish efficient delivery of vaccines in order to induce desired host immunity against infectious diseases.
format Online
Article
Text
id pubmed-6180194
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61801942018-10-18 Nanoparticle Vaccines Against Infectious Diseases Pati, Rashmirekha Shevtsov, Maxim Sonawane, Avinash Front Immunol Immunology Due to emergence of new variants of pathogenic micro-organisms the treatment and immunization of infectious diseases have become a great challenge in the past few years. In the context of vaccine development remarkable efforts have been made to develop new vaccines and also to improve the efficacy of existing vaccines against specific diseases. To date, some vaccines are developed from protein subunits or killed pathogens, whilst several vaccines are based on live-attenuated organisms, which carry the risk of regaining their pathogenicity under certain immunocompromised conditions. To avoid this, the development of risk-free effective vaccines in conjunction with adequate delivery systems are considered as an imperative need to obtain desired humoral and cell-mediated immunity against infectious diseases. In the last several years, the use of nanoparticle-based vaccines has received a great attention to improve vaccine efficacy, immunization strategies, and targeted delivery to achieve desired immune responses at the cellular level. To improve vaccine efficacy, these nanocarriers should protect the antigens from premature proteolytic degradation, facilitate antigen uptake and processing by antigen presenting cells, control release, and should be safe for human use. Nanocarriers composed of lipids, proteins, metals or polymers have already been used to attain some of these attributes. In this context, several physico-chemical properties of nanoparticles play an important role in the determination of vaccine efficacy. This review article focuses on the applications of nanocarrier-based vaccine formulations and the strategies used for the functionalization of nanoparticles to accomplish efficient delivery of vaccines in order to induce desired host immunity against infectious diseases. Frontiers Media S.A. 2018-10-04 /pmc/articles/PMC6180194/ /pubmed/30337923 http://dx.doi.org/10.3389/fimmu.2018.02224 Text en Copyright © 2018 Pati, Shevtsov and Sonawane. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Pati, Rashmirekha
Shevtsov, Maxim
Sonawane, Avinash
Nanoparticle Vaccines Against Infectious Diseases
title Nanoparticle Vaccines Against Infectious Diseases
title_full Nanoparticle Vaccines Against Infectious Diseases
title_fullStr Nanoparticle Vaccines Against Infectious Diseases
title_full_unstemmed Nanoparticle Vaccines Against Infectious Diseases
title_short Nanoparticle Vaccines Against Infectious Diseases
title_sort nanoparticle vaccines against infectious diseases
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180194/
https://www.ncbi.nlm.nih.gov/pubmed/30337923
http://dx.doi.org/10.3389/fimmu.2018.02224
work_keys_str_mv AT patirashmirekha nanoparticlevaccinesagainstinfectiousdiseases
AT shevtsovmaxim nanoparticlevaccinesagainstinfectiousdiseases
AT sonawaneavinash nanoparticlevaccinesagainstinfectiousdiseases